Display options
Cite
Tomizawa M, Shinozaki F, Motoyoshi Y, et al. Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway. Onco Targets Ther. 2013;6:1685-93doi: 10.2147/OTT.S50065.
Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., Sueishi, M., & Yoshida, T. (2013). Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway. OncoTargets and therapy, 61685-93. https://doi.org/10.2147/OTT.S50065
Tomizawa, Minoru, et al. "Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway." OncoTargets and therapy vol. 6 (2013): 1685-93. doi: https://doi.org/10.2147/OTT.S50065
Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T. Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway. Onco Targets Ther. 2013 Nov 18;6:1685-93. doi: 10.2147/OTT.S50065. eCollection 2013. PMID: 24273411; PMCID: PMC3836661.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2013 Nov 18;6:1685-93. doi: 10.2147/OTT.S50065. eCollection 2013.

Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway.

OncoTargets and therapy

Minoru Tomizawa, Fuminobu Shinozaki, Yasufumi Motoyoshi, Takao Sugiyama, Shigenori Yamamoto, Makoto Sueishi, Takanobu Yoshida

Affiliations

  1. Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital, Yotsukaido City, Chiba, Japan.

PMID: 24273411 PMCID: PMC3836661 DOI: 10.2147/OTT.S50065

Abstract

BACKGROUND: The Wnt pathway plays an important role in Hepatocarcinogenesis. We analyzed the association of the Wnt pathway with the proliferation of hepatoma cells using Wnt3a and niclosamide, a drug used to treat tapeworm infection.

METHODS: We performed an MTS assay to determine whether Wnt3a stimulated proliferation of Huh-6 and Hep3B human hepatoma cell lines after 72 hours of incubation with Wnt3a in serum-free medium. The cells were subjected to hematoxylin and eosin staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) after 48 hours of incubation. RNA was isolated 48 hours after addition of Wnt3a or niclosamide, and cyclin D1 expression levels were analyzed by real-time quantitative polymerase chain reaction. The promoter activity of T-cell factor was analyzed by luciferase assay 48 hours after transfection of TOPflash. Western blot analysis was performed with antibodies against β-catenin, dishevelled 2, and cyclin D1.

RESULTS: Cell proliferation increased with Wnt3a. Niclosamide suppressed proliferation with or without Wnt3a. Hematoxylin and eosin and TUNEL staining suggested that apoptosis occurred in cells with niclosamide. Cyclin D1 was upregulated in the presence of Wnt3a and downregulated with addition of niclosamide. The promoter activity of T-cell factor increased with Wnt3a, whereas T-cell factor promoter activity decreased with niclosamide. Western blot analysis showed that Wnt3a upregulated β-catenin, dishevelled 2, and cyclin D1, while niclosamide downregulated them.

CONCLUSION: Niclosamide is a potential candidate for the treatment of hepatoma.

Keywords: T-cell factor; Wnt3a; cyclin D1; luciferase assay; niclosamide

References

  1. Exp Ther Med. 2010 Sep;1(5):863-866 - PubMed
  2. Biochem Pharmacol. 2013 Jul 15;86(2):191-9 - PubMed
  3. PLoS One. 2009 Sep 22;4(9):e7124 - PubMed
  4. Dev Growth Differ. 2008 May;50(4):229-43 - PubMed
  5. Liver. 1996 Apr;16(2):123-9 - PubMed
  6. Dev Growth Differ. 2011 Sep;53(7):843-56 - PubMed
  7. Biochemistry. 2009 Nov 3;48(43):10267-74 - PubMed
  8. Med Lav. 1960 Oct 21;55:1937-8 - PubMed
  9. Viruses. 2010 Sep;2(9):2108-33 - PubMed
  10. J Hepatol. 2010 Jun;52(6):921-9 - PubMed
  11. Cell Signal. 2008 Apr;20(4):581-9 - PubMed
  12. J Cell Biochem. 2007 Sep 1;102(1):161-70 - PubMed
  13. J Natl Cancer Inst. 2011 Jul 6;103(13):1018-36 - PubMed
  14. Cancer Res. 2011 Jun 15;71(12):4172-82 - PubMed
  15. Arch Virol. 2011 Jun;156(6):1013-23 - PubMed
  16. Mol Biol Cell. 2008 Aug;19(8):3290-8 - PubMed
  17. PLoS Negl Trop Dis. 2012;6(3):e1594 - PubMed
  18. PLoS One. 2011;6(11):e27496 - PubMed
  19. Br J Cancer. 2008 Jul 8;99(1):143-50 - PubMed
  20. Int J Oncol. 2009 Oct;35(4):861-6 - PubMed
  21. World J Gastroenterol. 2010 Apr 21;16(15):1854-8 - PubMed
  22. Mol Cancer Ther. 2012 Aug;11(8):1703-12 - PubMed
  23. EMBO J. 2001 May 1;20(9):2160-70 - PubMed
  24. Clin Cancer Res. 2007 Jul 15;13(14):4042-5 - PubMed
  25. PLoS One. 2012;7(6):e39668 - PubMed

Publication Types